Latest1 information on COVID-19
©2022 Stanford Medicine
Imaging and Biomarkers of Hypoxia in Solid Tumors
Not Recruiting
Trial ID: NCT01123005
Purpose
Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human
cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the
tumor with oxygenated blood. It is currently understood that hypoxic tumors are more
aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue
biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to
measure tumor hypoxia.
Official Title
Imaging and Biomarkers of Hypoxia in Solid Tumors
Stanford Investigator(s)
Billy W Loo, Jr, MD PhD FASTRO FACR
Professor of Radiation Oncology (Radiation Therapy)
Heather Wakelee
Professor of Medicine (Oncology)
Quynh-Thu Le, MD
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
John B. Sunwoo, MD
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor, by courtesy, of Dermatology
Joseph Shrager
Professor of Cardiothoracic Surgery
Maximilian Diehn, MD, PhD
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Edward J. Damrose, MD, FACS
Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Anesthesiology, Perioperative & Pain Medicine
Eligibility
INCLUSION CRITERIA
- Any solid tumor malignancies of any stage meeting all of the following criteria:
Minimum tumor dimension is at least 1 cm (to ensure it is above the detection
threshold of PET imaging). Examples include but are not limited to: locally advanced
squamous cell carcinoma of the head and neck to be treated by either initial surgery
or primary chemoradiotherapy; inoperable non-small cell lung cancer or pancreatic
carcinoma to be treated with stereotactic radiotherapy, which may be biopsied again at
the time of percutaneous needle delivery of implanted fiducial markers.
- Patients with newly diagnosed malignancies should not have initiated treatment for
their disease before participating in this study. Patients with recurrent or second
malignancies may have had prior therapy as appropriate for their disease, but should
have completed all prior treatment at least 30 days before participation in this study
and should not have initiated new treatment for the current problem.
- Greater than or equal to eighteen years of age.
- Sufficiently healthy to tolerate all study procedures.
- Organ and marrow function sufficient to undergo planned therapy.
- Ability to understand and the willingness to sign a written informed consent document.
EXCLUSION CRITERIA
• Pregnant or nursing
Intervention(s):
drug: EF5
drug: Carbogen
procedure: PET Scan
drug: Dichloroacetate
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061